Related Experiment Video
Updated: May 17, 2026
12:30
Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
Published on: August 12, 2014
Nitric oxide donors for cardiovascular implant applications
Noora Naghavi1, Achala de Mel, Omid Sadeghi Alavijeh
1UCL Centre for Nanotechnology & Regenerative Medicine, University College London, UK.
Small (Weinheim an Der Bergstrasse, Germany)
|November 9, 2012
Summary
This review explores nitric oxide (NO) donors integrated into biomaterials for advanced cardiovascular devices. These NO-eluting materials aim to prevent blood clots and improve healing for better patient outcomes.
Area of Science:
- Biomaterials Science
- Cardiovascular Engineering
- Medical Device Technology
Background:
- Cardiovascular diseases are a growing concern in aging populations, increasing the need for effective blood-contacting devices like heart valves, stents, and grafts.
- Nitric oxide (NO) plays a crucial role in maintaining vascular health and hemostasis by preventing thrombosis and intimal hyperplasia.
- Current cardiovascular devices often face challenges related to biocompatibility and thrombosis, highlighting the need for improved material strategies.
Purpose of the Study:
- To review the application of nitric oxide (NO) donors within biomaterials for cardiovascular therapies.
- To explore methods for optimizing NO release kinetics from biomaterials.
- To discuss the potential of NO-eluting biomaterials in fabricating next-generation cardiovascular devices.
Main Methods:
- Review of literature on nitric oxide donors (N-diazeniumdiolates, S-nitrosothiols) and their incorporation into polymeric scaffolds, microparticles, and nanomaterials.
- Analysis of studies investigating the local release of NO from biomaterials for cardiovascular applications.
- Examination of clinical applications and fabrication techniques for NO-eluting cardiovascular devices.
Main Results:
- Nitric oxide (NO) donors, such as N-diazeniumdiolates and S-nitrosothiols, are effective in preventing thrombosis and intimal hyperplasia when released from biomaterials.
- Polymeric scaffolds incorporating micro- and nanomaterials offer promising strategies for controlled NO release and optimized kinetic profiles.
- The local elution of NO from cardiovascular devices enhances endothelialization and improves overall device performance.
Conclusions:
- Biomaterials incorporating nitric oxide (NO) donors represent a significant advancement in cardiovascular device technology.
- Optimized NO release from these materials can effectively prevent thrombosis and intimal hyperplasia, while promoting endothelialization.
- This approach holds great promise for the development of next-generation cardiovascular devices with improved safety and efficacy.
More Related Videos
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...